Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19401565 | 0.92 | FAAH (0.58) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL840681 | 0.92 | — | — | |
| SCHEMBL9921404 | 0.90 | CASP2 (0.48) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL17740222 | 0.90 | CASP2 (0.48) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL10124173 | 0.90 | PHF8 (0.52) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL10125720 | 0.90 | CTSD (0.65) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL16302656 | 0.89 | FAAH (0.63) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL16392735 | 0.88 | CASP2 (0.47) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL1171551 | 0.88 | CASP2 (0.47) | CASP2MCL1NAAACNR1FAAH | |
| SCHEMBL1298444 | 0.88 | CASP2 (0.47) | CASP2MCL1NAAACNR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-7214715-B2 | Compounds to treat Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
| EP-0382548-B1 | Thermoplastic resin composition | SUMITOMO CHEMICAL CO (JP) | 1994-06-29 | — | — | EP | disclosed |
| US-5116906-A | Molding materials | SUMITOMO CHEMICAL CO., LTD. (JP) | 1992-05-26 | — | — | US | disclosed |
| EP-0382548-A2 | Thermoplastic resin composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4782005-A | N,N'-diorgano dicarboxamides as oxygen inhibitors in radiation sensitive acrylate compositions | POLYCHROME CORP. (US) | 1988-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | CASP2 3107/4885MCL1 4864/4885NAAA 107/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | CASP2 1368/4885MCL1 3233/4885NAAA 48/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | CASP2 1112/4885MCL1 3645/4885NAAA 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.